Sign in

NCT03152669Completed

The Extended Salford Lung Study ("Ex-SLS") Data Access Project

Source: ClinicalTrials.gov · Last updated 7 Jul 2026

Brief summary (registry, in English)

The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk, treatment and progression. This proposal seeks to collect additional subject-level data from SLS patients via their electronic medical records (encompassing past and future data for up to 10 years from the date of consent) and via a one-off patient questionnaire administered at the time of consent.

Status (registry)
Completed
Study type
Observational
Enrollment
1183 (actual)
First submitted
8 May 2017
Start date
15 Apr 2018
Primary completion date
5 Jul 2025
Lead sponsor
GlaxoSmithKline
Diseases
Asthma, COPD
NCT number
NCT03152669

What you commit to

  • Study type: Observational
  • Participants enrolled: 1183
  • From 15 Apr 2018 to the primary completion date, 5 Jul 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Subjects who were lost to follow-up/moved away, withdrew consent or died during or subsequent to the original SLS studies.
  • Subjects considered (at the discretion of the investigator) as too ill to participate or without the mental capacity to provide informed consent.

Who the study is looking for

  • Subjects who were randomized to treatment in the original SLS studies
  • Subjects who are able to, and choose to, provide written consent for the additional information to be collected.

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
GSK Investigational Site
Coordinator of this site? Confirm its status
ManchesterUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.